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Rheumatoid arthritis (RA) is a common autoimmune disorder which shows clinical heterogeneity. IT 
has multiple treatment options and there is individual variation in response to treatment. These 
features make RA an ideal condition to develop biomarkers for its pre-clinical detection, diagnosis, 
subtyping, prognostic stratification and selection of most optimal treatment. While a number of 
markers have been assessed for their biomarker quality, currently no marker has the statistical 
properties of a biomarker to be considered as a good classifier. In this chapter, a general review of 
biomarkers is followed by a detailed discussion of biomarker candidates for various aspects of RA. It 
is unlikely that a single marker will ever be sufficiently powerful as a biomarker, but combinations of 
clinical, biochemical, genetic, epigenetic, proteomic and metabolomic markers have the strongest 
potential to fulfill the requirements of biomarkers. Given the high heritability of RA and the progress 
in methodology of genome-wide association studies, genetic markers are the most promising group 
to be developed as biomarkers, in particular when epigenetic markers become more widely used. It 
is possible that in the near future, biomarkers with documented clinical utility will be available for use 
in clinical decision making and will most probably use multiple omics platforms. 
 
 
